Literature DB >> 1461136

Beta-cell hypersecretion and not reduced hepatic insulin extraction is the main cause of hyperinsulinemia in obese nondiabetic subjects.

A Kautzky-Willer1, G Pacini, B Ludvik, G Schernthaner, R Prager.   

Abstract

Obesity is characterized by peripheral hyperinsulinemia, for which either beta-cell hypersecretion, diminished hepatic insulin extraction, or both may be responsible. To clarify this issue, we investigated insulin secretion and hormone hepatic extraction in 18 nondiabetic obese patients (body mass index [BMI], 39 +/- 1.3 kg/m2) and 18 healthy, lean control subjects (BMI, 21.3 +/- 0.7 kg/m2). Body fat distribution was calculated by measuring the waist to hip ratio (WHR). A highly reduced tissue insulin sensitivity (2.4 +/- 0.5 v 9.5 +/- 1.5 10(4).min-1/[microU/mL], P > .0005) and glucose effectiveness, ie, glucose's ability to stimulate its own disappearance at basal insulin (16 +/- 2 v 30 +/- 3 10(3).min-1, P > .005), were found in the overweight subjects compared with the controls. The basal (76 +/- 14 v 37 +/- 4 pmol/L/min) and total (377,848 +/- 5,562 v 16,864 +/- 1,850 pmol/L) prehepatic insulin secretion and the basal (15 +/- 2 v 7 +/- 0.7 pmol/L/min) and total (8,286 +/- 2,009 v 2,840 +/- 210 pmol/L) posthepatic insulin delivery were significantly higher in the overweight subjects compared with the controls (P < .005), whereas the mean hepatic insulin extraction did not differ (77.8% +/- 2.6% v 79.5% +/- 2.6%). A significant inverse correlation was found between the hepatic insulin extraction and the WHR (r = .5, P > .04), signifying the importance of fat distribution in insulin metabolism. The obese patients were subdivided into two subgroups according to their glucose tolerance; eight patients exhibited a normal tolerance and the remaining 10 were intolerant.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1461136     DOI: 10.1016/0026-0495(92)90100-o

Source DB:  PubMed          Journal:  Metabolism        ISSN: 0026-0495            Impact factor:   8.694


  8 in total

1.  Failure to adequately adapt reduced insulin sensitivity with increased insulin secretion in women with impaired glucose tolerance.

Authors:  H Larsson; B Ahrén
Journal:  Diabetologia       Date:  1996-09       Impact factor: 10.122

2.  The incretin effect in obese adolescents with and without type 2 diabetes: impaired or intact?

Authors:  Benedikt A Aulinger; Torsten P Vahl; Ron L Prigeon; David A D'Alessio; Deborah A Elder
Journal:  Am J Physiol Endocrinol Metab       Date:  2016-03-15       Impact factor: 4.310

3.  Role of islet amyloid polypeptide secretion in insulin-resistant humans.

Authors:  A Kautzky-Willer; K Thomaseth; G Pacini; M Clodi; B Ludvik; C Streli; W Waldhäusl; R Prager
Journal:  Diabetologia       Date:  1994-02       Impact factor: 10.122

4.  Insulin resistance and autonomic function in traumatic lower limb amputees.

Authors:  E Peles; S Akselrod; D S Goldstein; H Nitzan; M Azaria; S Almog; D Dolphin; H Halkin; M Modan
Journal:  Clin Auton Res       Date:  1995-10       Impact factor: 4.435

5.  An Analysis of Glucose Effectiveness in Subjects With or Without Type 2 Diabetes via Hierarchical Modeling.

Authors:  Shihao Hu; Yuzhi Lu; Andrea Tura; Giovanni Pacini; David Z D'Argenio
Journal:  Front Endocrinol (Lausanne)       Date:  2021-03-29       Impact factor: 5.555

6.  Effect of body mass index on diabetogenesis factors at a fixed fasting plasma glucose level.

Authors:  Jiunn-Diann Lin; Chun-Hsien Hsu; Chung-Ze Wu; An-Tsz Hsieh; Chang-Hsun Hsieh; Yao-Jen Liang; Yen-Lin Chen; Dee Pei; Jin-Biou Chang
Journal:  PLoS One       Date:  2018-01-29       Impact factor: 3.240

Review 7.  Glucose effectiveness: Lessons from studies on insulin-independent glucose clearance in mice.

Authors:  Bo Ahrén; Giovanni Pacini
Journal:  J Diabetes Investig       Date:  2020-12-01       Impact factor: 4.232

8.  Impact of Incretin Hormone Receptors on Insulin-Independent Glucose Disposal in Model Experiments in Mice.

Authors:  Tina Ovlund; Giovanni Pacini; Bo Ahrén
Journal:  Front Endocrinol (Lausanne)       Date:  2021-06-08       Impact factor: 5.555

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.